Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CTSA | P10619 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21631933 | 0.88 | L3MBTL1 (0.51) | L3MBTL1POLBHTTNPSR1SMN1; SMN2 | |
| SCHEMBL21632162 | 0.86 | POLB (0.50) | L3MBTL1POLBHTTNPSR1SMN1; SMN2 | |
| SCHEMBL21632110 | 0.84 | KMT2A (0.48) | L3MBTL1POLBHTTNPSR1KMT2A | |
| SCHEMBL21632117 | 0.82 | FFAR1 (0.41) | L3MBTL1POLBHTTNPSR1CTSA | |
| SCHEMBL15248915 | 0.82 | ALDH1A1 (0.44) | L3MBTL1HTTSMN1; SMN2KMT2ALMNA | |
| SCHEMBL21656298 | 0.81 | HTT (0.46) | L3MBTL1POLBHTTNPSR1SMN1; SMN2 | |
| SCHEMBL21632320 | 0.81 | MEN1 (0.47) | NPSR1KMT2ALMNACTSAALDH1A1 | |
| SCHEMBL433240 | 0.80 | FFAR1 (0.52) | SMN1; SMN2KMT2ALMNAALDH1A1SGMS2 | |
| SCHEMBL14881735 | 0.79 | HPGD (0.40) | FFAR1 | |
| SCHEMBL21632346 | 0.79 | KMT2A (0.48) | L3MBTL1POLBHTTNPSR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136296-B2 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-05 | — | — | US | disclosed |
| US-20200031775-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031775-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | AADAC, NAT1, EPX | L3MBTL1 3686/4885POLB 3807/4885HTT 2899/4885 |
| US-11136296-B2 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof | AADAC, NAT1, EPX | L3MBTL1 3686/4885POLB 3807/4885HTT 2899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.